🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Keynote by Sherene Loi at #ESMOBreast25 🔹 Pregnancy & breastfeeding may reprogram the breast immune environment, enhancing early cancer detection. 🔹 HR+ breast cancer may respond to immunotherapy if biologically selected (CheckMate 7FL). ESMO - Eur. Oncology OncoAlert OncoDaily

Good morning all. After yesterday's excitement about the CHALLENGE exercise trial, here is my critical appraisal on Sensible Medicine #ASCO25

Important to note that in the randomized trial showing equivalence of TCHP and THP that patients got 18 weeks of therapy with THP (not the more common 12 weeks) which might account for both higher pCR rates and lack of need for carboplatin.

Oral abstract session at #ASCO25 with 15-y follow-up data from ETOP IBCSG Partners Foundation SOFT & TEXT trials…proper risk stratification is needed to optimize adjuvant endocrine therapy in premenopausal women with #BreastCancer OncoAlert

ASCENT-04- first randomized phase III study of ADC+ IO. #asco25. nice to see immune AEs so low in SG arm. 🤔Effect of targeted 🚩tumor death vs chemo non specific normal tissue tox?

bravo #ASCO25 👏👏👏👏

👏👏amazing 40m med PFS with TDXD+P v 20m THP. If 2L TDXD (DB03) is 28m PFS v 6m TDM1, does the maths favour 1L THP➡️2L TDXD? +add Palbo? Esp as 1L TDXD may make 2L TDM1 less effective (down reg HER2). Potentially 1L DB09 may ⬆️ CNS control. Def need OS - are some patients

informative censoring vs ITT analyses.-a problem for all studies of exercise in cancer patients I suspect

🚩Final results of IMpassion031👏neoadj Atezo in early #TNBC Final EFS HR~ Gepardouze. ctDNA neg by Signatera not sensitive enough to say patients are cured but small % who were pos did poorly. Hopefully next gen ctDNA assays will be better. #bcsm Nature Medicine

⭐️This study reinforces that treating upfront with the strongest targeted 🎯 combination will alter the natural history of disease & ⬆️ OS. We've seen it for #HER2 Better pharmacology has & will improve tolerabilty, AE profile & 🔽discontinuations NEJM #bcsm #breastcancer

Given recent amazing results from Rand P3 study by Zheng et al, #ASCO25 on Chrono-IO (PD-1 before 3 pm vs after; HR 0.42), #circadian clocks are topical- but is it fit-patient bias? Broad aspirational review below from Nature Cancer OncoAlert ⭐️also many new drugs have PK/PD

😂🤩 Andy Murray

“Who decides who decides?” An editorial based on Rebecca Campbell & Laura Bukavina’s work in which we explore how altmetrics & digital clout are shaped by systemic bias. Honored to cowrite this with Stephanie Graff, MD, FACP, FASCO 🔗 ascopubs.org/doi/10.1200/OP… #MedTwitter #WomenInMedicine

JCOG1017 trial found that primary tumor resection (PTR) did not prolong overall survival in de novo Stage IV breast cancer. However, it improved local control and might benefit subsets like premenopausal patients or those with single-organ metastasis. JCOGbreast Tadahiko Shien

🏃‍♀️🏋️🏋️‍♂️🎾👟Further evidence on the benefit of physical activity #exercise #strength training for chronic medical conditions from a RCT rdcu.be/evps3 Nature Medicine

(Breast) Cancer care shouldn’t be a luxury. We lose lives not just to cancer, but to lack of access, high costs, and trials that exclude too many. Innovation must reach every patient, everywhere! nature G Curigliano MD PhD Sherene Loi, MD ESMO - Eur. Oncology ASCO Breast Cancer Now Tatiana Prowell, MD Union for International #CancerControl

#bcsm 💊💉we really need more efficacious drugs!